Trials / Completed
CompletedNCT00073255
Safety and Pharmacokinetics (PK) of hOKT3g1 (Ala-Ala) in Type 1 Diabetes Mellitus (T1DM)
Evaluation of Tolerability, Safety, and Pharmacokinetics of hOKT3g1 (Ala-Ala)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (planned)
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NIH
- Sex
- All
- Age
- 8 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
To assess the tolerability and safety of hOKT3g1 (Ala-Ala) after a 12-day dosing regimen administered via intravenous infusion. To assess the pharmacokinetics of hOKT3g1 (Ala-Ala).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hokt3g1 (ALA-ALA) |
Timeline
- Start date
- 2003-06-01
- Completion
- 2005-12-01
- First posted
- 2003-11-20
- Last updated
- 2010-01-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00073255. Inclusion in this directory is not an endorsement.